The rising incidence of iron deficiency anemia, particularly among women due to menstrual cycles, is a significant driver for the market. For instance, the National Family Health Survey (2019-21) ...

CKD anemia market to hit $5.3B by 2034, fueled by HIF-PH inhibitor innovation, despite rising generic competition and persistent unmet patient needs.

Raji Shameem, MD discusses how luspatercept has become his preferred frontline treatment for lower-risk MDS patients with anemia due to its superior efficacy compared to ESAs in the COMMANDS trial, ...

The National Sickle Cell Anaemia Elimination Mission, launched in 2023, aims to eradicate the disease by 2047. Spearheaded by CSIR under the leadership of Director General Nallathamby Kalaiselvi, the ...